Valuation: Clene Inc.

Market Cap 67.47M 58.44M 54.47M 50.1M 94.58M 6.42B 95.64M 640M 251M 3.21B 253M 248M 10.63B P/E 2026 *
-2.96x
P/E 2027 * -3.59x
Enterprise Value 54.07M 46.83M 43.65M 40.15M 75.8M 5.14B 76.64M 513M 201M 2.57B 203M 199M 8.52B EV / Sales 2026 *
261x
EV / Sales 2027 * 1.95x
Free-Float
82.94%
Yield 2026 *
-
Yield 2027 * -
1 day+2.56%
1 week+15.68%
Current month+8.87%
1 month-9.15%
3 months-17.02%
6 months+39.29%
Current year-6.98%
1 week 4.78
Extreme 4.78
5.48
1 month 4.63
Extreme 4.63
6.55
Current year 3.88
Extreme 3.88
8.67
1 year 3.5
Extreme 3.5001
13.5
3 years 2.28
Extreme 2.2801
15.57
5 years 2.28
Extreme 2.2801
196.8
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 65 01/11/2015
Director/Board Member 53 01/09/2019
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
4/5/26 Sell -72,884 0.6188%
19/2/26 Free

Founder

3,306 0.0281%
19/2/26 Free

Director

3,168 0.0269%
Change 5-day change 1-year change 3-year change Capi.($)
+2.56%+15.68%+47.97%-58.64% 67.47M
+4.35%+19.90%+60.59%+95.21% 62.53B
+2.83%-3.48%+24.97%+69.33% 52.43B
-0.55%-2.26%-18.20%-7.77% 23.1B
+1.79%-2.64%-10.05%+359.05% 21.4B
+0.40%+5.29%+30.11%-9.63% 21.17B
+0.75%+1.34%+32.22%-25.54% 17.76B
+9.88%+19.73%+229.67%+385.49% 15.47B
+2.08%-3.28%+21.67%+564.59% 14.68B
+0.38%+1.39%+49.76%+177.04% 14.08B
Average +2.45%+3.87%+46.87%+154.91% 24.27B
Weighted average by Cap. +2.71%+4.59%+42.22%+136.70%

Financials

2026 *2027 *
Net sales 207K 180K 167K 154K 291K 19.72M 294K 1.97M 772K 9.87M 779K 762K 32.68M 23.64M 20.48M 19.09M 17.56M 33.15M 2.25B 33.52M 224M 88.04M 1.12B 88.8M 86.85M 3.73B
Net income -25.09M -21.73M -20.26M -18.63M -35.18M -2.39B -35.57M -238M -93.44M -1.19B -94.25M -92.17M -3.95B -27.55M -23.86M -22.24M -20.46M -38.62M -2.62B -39.05M -261M -103M -1.31B -103M -101M -4.34B
Net Debt -13.4M -11.61M -10.82M -9.95M -18.78M -1.27B -18.99M -127M -49.9M -638M -50.33M -49.22M -2.11B -21.4M -18.53M -17.28M -15.89M -30M -2.03B -30.33M -203M -79.69M -1.02B -80.37M -78.6M -3.37B
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
-
Date Price Change Volume
06/08/26 US$5.460 +3.41% 27,492
04/08/26 US$5.280 +1.73% 45,982
03/08/26 US$5.190 +3.49% 27,258
31/07/26 US$5.015 -0.50% 33,748
30/07/26 US$5.040 +6.78% 37,350
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.280USD
Average target price
32.20USD
Spread / Average Target
+509.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock